122 related articles for article (PubMed ID: 38303191)
21. Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results.
Perez EA; López-Vega JM; Petit T; Zamagni C; Easton V; Kamber J; Restuccia E; Andersson M
Breast Cancer Res; 2016 Dec; 18(1):126. PubMed ID: 27955684
[TBL] [Abstract][Full Text] [Related]
22. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.
Swain SM; Miles D; Kim SB; Im YH; Im SA; Semiglazov V; Ciruelos E; Schneeweiss A; Loi S; Monturus E; Clark E; Knott A; Restuccia E; Benyunes MC; Cortés J;
Lancet Oncol; 2020 Apr; 21(4):519-530. PubMed ID: 32171426
[TBL] [Abstract][Full Text] [Related]
23. Impact of Pertuzumab and Ado-Trastuzumab Emtansine on Cumulative Avoidance of Recurrence Among Women Treated for Locally Advanced, Inflammatory, or Early-Stage Nonmetastatic HER2-Positive Breast Cancer in the United States.
Sussell JA; Press DJ; Hansen SA; Kim E; Du Toit Y; Fung A
Adv Ther; 2023 Sep; 40(9):3857-3874. PubMed ID: 37358705
[TBL] [Abstract][Full Text] [Related]
24. Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study.
Martin M; Fumoleau P; Dewar JA; Albanell J; Limentani SA; Campone M; Chang JC; Patre M; Strasak A; de Haas SL; Xu J; Garcia-Saenz JA
Ann Oncol; 2016 Jul; 27(7):1249-56. PubMed ID: 27052654
[TBL] [Abstract][Full Text] [Related]
25. Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study.
Gianni L; Bisagni G; Colleoni M; Del Mastro L; Zamagni C; Mansutti M; Zambetti M; Frassoldati A; De Fato R; Valagussa P; Viale G
Lancet Oncol; 2018 Feb; 19(2):249-256. PubMed ID: 29326029
[TBL] [Abstract][Full Text] [Related]
26. [Responses to primary systemic therapy for breast cancer as assessed by hormone receptor and HER2 status].
Hirano A; Shimizu T; Kamimura M; Ogura K; Kim N; Setoguchi Y; Okubo F; Kinoshita J; Ogawa K; Fujibayashi M
Gan To Kagaku Ryoho; 2011 May; 38(5):771-6. PubMed ID: 21566435
[TBL] [Abstract][Full Text] [Related]
27. [A Case of Luminal-HER2 Advanced Breast Cancer with Liver Metastasis Showed Pathological Complete Response to the Therapy with Pertuzumab plus Trastuzumab plus Docetaxel].
Hamaoka A; Matsuda T; Konishi E; Taguchi T
Gan To Kagaku Ryoho; 2016 Sep; 43(9):1097-100. PubMed ID: 27628551
[TBL] [Abstract][Full Text] [Related]
28. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.
Baselga J; Cortés J; Kim SB; Im SA; Hegg R; Im YH; Roman L; Pedrini JL; Pienkowski T; Knott A; Clark E; Benyunes MC; Ross G; Swain SM;
N Engl J Med; 2012 Jan; 366(2):109-19. PubMed ID: 22149875
[TBL] [Abstract][Full Text] [Related]
29. [Two Cases of Unresectable/Advanced Breast Cancer with Pathological Complete Response after Combination Chemotherapy with Pertuzumab. Trastuzumab, and Docetaxel].
Tomida K; Kawai Y; Mori T; Kitamura M; Kato H; Sakai S; Shimizu T; Umeda T; Tatsumi M; Shimada K; Tani M
Gan To Kagaku Ryoho; 2018 Dec; 45(13):2435-2437. PubMed ID: 30692489
[TBL] [Abstract][Full Text] [Related]
30. A case of metastatic breast cancer with outgrowth of HER2-negative cells after eradication of HER2-positive cells by humanized anti-HER2 monoclonal antibody (trastuzumab) combined with docetaxel.
Kunitomo K; Inoue S; Ichihara F; Kono K; Fujii H; Matsumoto Y; Ooi A
Hum Pathol; 2004 Mar; 35(3):379-81. PubMed ID: 15017597
[TBL] [Abstract][Full Text] [Related]
31. Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.
Kawajiri H; Takashima T; Kashiwagi S; Noda S; Onoda N; Hirakawa K
Expert Rev Anticancer Ther; 2015 Jan; 15(1):17-26. PubMed ID: 25494663
[TBL] [Abstract][Full Text] [Related]
32. Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer.
Bianchini G; Kiermaier A; Bianchi GV; Im YH; Pienkowski T; Liu MC; Tseng LM; Dowsett M; Zabaglo L; Kirk S; Szado T; Eng-Wong J; Amler LC; Valagussa P; Gianni L
Breast Cancer Res; 2017 Feb; 19(1):16. PubMed ID: 28183321
[TBL] [Abstract][Full Text] [Related]
33. Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-up.
Wang R; Smyth LM; Iyengar N; Chandarlapaty S; Modi S; Jochelson M; Patil S; Norton L; Hudis CA; Dang CT
Oncologist; 2019 Aug; 24(8):e646-e652. PubMed ID: 30602614
[TBL] [Abstract][Full Text] [Related]
34. Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study.
Bilici A; Olmez OF; Kaplan MA; Oksuzoglu B; Sezer A; Karadurmus N; Cubukcu E; Sendur MAN; Aksoy S; Erdem D; Basaran G; Cakar B; Shbair ATM; Arslan C; Sumbul AT; Sezgin Goksu S; Karadag I; Cicin I; Gumus M; Selcukbiricik F; Harputluoglu H; Demirci U
Acta Oncol; 2023 Apr; 62(4):381-390. PubMed ID: 37083566
[TBL] [Abstract][Full Text] [Related]
35. Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study.
Kuemmel S; Tondini CA; Abraham J; Nowecki Z; Itrych B; Hitre E; Karaszewska B; Juárez-Ramiro A; Morales-Vásquez F; Pérez-García JM; Cardona-Huerta S; Monturus E; Sequi M; Restuccia E; Benyunes M; Martín M
Breast Cancer Res Treat; 2021 Jun; 187(2):467-476. PubMed ID: 33748921
[TBL] [Abstract][Full Text] [Related]
36. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline.
Giordano SH; Temin S; Kirshner JJ; Chandarlapaty S; Crews JR; Davidson NE; Esteva FJ; Gonzalez-Angulo AM; Krop I; Levinson J; Lin NU; Modi S; Patt DA; Perez EA; Perlmutter J; Ramakrishna N; Winer EP;
J Clin Oncol; 2014 Jul; 32(19):2078-99. PubMed ID: 24799465
[TBL] [Abstract][Full Text] [Related]
37. Neoadjuvant weekly paclitaxel and carboplatin with trastuzumab and pertuzumab in HER2-positive breast cancer: a Brown University Oncology Research Group (BrUOG) study.
Lopresti ML; Bian JJ; Sakr BJ; Strenger RS; Legare RD; Fenton M; Witherby SM; Dizon DS; Pandya SV; Stuckey AR; Edmondson DA; Gass JS; Emmick CM; Graves TA; Cutitar M; Olszewski AJ; Sikov WM
Breast Cancer Res Treat; 2021 Aug; 189(1):93-101. PubMed ID: 34086171
[TBL] [Abstract][Full Text] [Related]
38. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial.
Tolaney SM; Wardley AM; Zambelli S; Hilton JF; Troso-Sandoval TA; Ricci F; Im SA; Kim SB; Johnston SR; Chan A; Goel S; Catron K; Chapman SC; Price GL; Yang Z; Gainford MC; André F
Lancet Oncol; 2020 Jun; 21(6):763-775. PubMed ID: 32353342
[TBL] [Abstract][Full Text] [Related]
39. Pertuzumab: a review of its use for first-line combination treatment of HER2-positive metastatic breast cancer.
McCormack PL
Drugs; 2013 Sep; 73(13):1491-502. PubMed ID: 23982598
[TBL] [Abstract][Full Text] [Related]
40. Complete response in patient with liver metastasis of HER2-positive breast cancer following therapy with margetuximab: a case report.
Chang H; Hu T; Hu J; Ding T; Wang Q; Cheng J
Anticancer Drugs; 2023 Aug; 34(7):883-887. PubMed ID: 36730303
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
